The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huffnagle, G. B.
Right arrow Articles by Kuziel, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huffnagle, G. B.
Right arrow Articles by Kuziel, W. A.
The Journal of Immunology, 1999, 163: 4642-4646.
Copyright © 1999 by The American Association of Immunologists

CUTTING EDGE

Cutting Edge: Role of C-C Chemokine Receptor 5 in Organ-Specific and Innate Immunity to Cryptococcus neoformans1

Gary B. Huffnagle2,*, Lisa K. McNeil*, Roderick A. McDonald*, Juneann W. Murphy{dagger}, Galen B. Toews*, Nobuyo Maeda{ddagger} and William A. Kuziel§

* Pulmonary Division, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109; {dagger} Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190; {ddagger} Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599; and § Department of Molecular Genetics and Microbiology and Institute for Cellular and Molecular Biology, University of Texas, Austin, TX 78712


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
After intratracheal inoculation of the AIDS-associated pathogen Cryptococcus neoformans, 12-wk survival was >90% for CCR5+/+ mice but <25% for CCR5-/- mice. There were no defects in lung leukocyte recruitment (wk 5), pulmonary clearance, or delayed-type hypersensitivity in CCR5-/- mice. However, CCR5-/- mice had defects in leukocyte recruitment into the brain and, strikingly, in elimination of cryptococcal polysaccharide from the brain. In nonimmune CCR5-/- mice, there was a significant defect in macrophage recruitment after challenge with shed cryptococcal products (C. neoformans filtrate Ag) but not other nonspecific stimuli. Thus, CCR5 plays specific roles in innate immunity and organ-specific leukocyte trafficking during host defense against C. neoformans.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
The CC chemokine receptor CCR5 is a coreceptor for HIV infection (1, 2, 3, 4); however, the normal biological function of CCR5 largely remains to be elucidated. CCR5 is expressed on a number of hemopoietic (including lymphocytes, macrophages, and granulocytes) and nonhemopoietic cells (5). Ligands for this receptor include MIP-1{alpha},3 MIP-1ß, RANTES, and HIV gp120 (6, 7). CCR5 expression is greater on CD45RO+ (memory) than on CD45RO- (naive) T cells and enhanced on T cells at sites of inflammatory reactions (8). Individuals that are homozygous or heterozygous for mutant CCR5 alleles do not appear to exhibit defective T cell responses (9, 10, 11, 12). Zhou et al. (13) found that CCR5 knockout mice displayed normal or enhanced T cell responses to the stimuli tested and did not exhibit leukocyte recruitment defects. This latter observation is in contrast with those in CCR1 and CCR2 knockout mice, which have significant defects in leukocyte recruitment (14, 15, 16, 17, 18). Mutations in CCR5 are not found in individuals of African or Asian ancestry (10, 12). Therefore, it still remains to be determined what role CCR5 plays in leukocyte trafficking and immunity during infection.

The objective of our studies was to determine whether expression of CCR5 was required for host defense against the encapsulated yeast Cryptococcus neoformans. Protective immunity against this AIDS-associated opportunistic pathogen requires the development of T cell-mediated immunity (reviewed in Ref. 19). C. neoformans is acquired via the respiratory tract and disseminates to the CNS (20). Cryptococcal meningitis is common late in the pathogenesis of HIV infection (20). In murine models of pulmonary cryptococcosis, the T cell-mediated immune response in the lungs is a Th1-type response that requires CD4+ T cells, CD8+ T cells, monocyte chemotactic protein-1, and MIP-1{alpha} for leukocyte recruitment and cryptococcal clearance (reviewed in Ref. 19). After dissemination from the lungs, host defense in the CNS also requires CD4+ T cells, IFN-{gamma}, TNF-{alpha}, and mononuclear cell recruitment (reviewed in Refs. 21 and 22). Our studies focused on the role of CCR5 in immunity against C. neoformans at the sites of primary infection (lung) and disseminated infection (brain).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
C. neoformans

C. neoformans strain 145 was obtained from the American Type Culture Collection (62070; Rockville, MD). Strain 145 was originally isolated from the cerebrospinal fluid of a patient with cryptococcal meningitis. C. neoformans organisms were grown and prepared as previously described (23). Pulmonary infection was initiated in mice via intratracheal inoculation of C. neoformans using a 30-µl inoculum containing 104 CFU (23).

Mice

CCR5+/+ mice (B6129F2/J, University of Michigan breeding colony and The Jackson Laboratory, Bar Harbor, ME) and CCR5-/- mice (B6129F2/J-Cmkbr5tm1Kuz, University of Michigan breeding colony) were housed under specific pathogen-free conditions in enclosed filter top cages. The CCR5+/+ and CCR5-/- lines of mice were B6129F2 background and large enough n values were used in the experiments to control for potential variance of responses within this strain of mice. CCR5+/+ and CCR5-/- mice were generated that were homozygous for 129-derived sequences flanking the CCR5 locus (as described previously (17)) but differed in deletion or presence of the single CCR5 exon.4 These mice were bred as homozygotes since their derivation. CCR5+/+ 129B6F2/J mice supplied by The Jackson Laboratory were also used in some experiments, and there was no significant difference between the two sources of CCR5+/+ mice. Mice were 8–16 wk of age at the time of infection and there was no age-related differences in the responses of these mice to C. neoformans infection.

Leukocyte recruitment into C. neoformans Ag-instilled gelatin sponges

The Ag preparation for the assay (CneF) was prepared by concentrating and dialyzing the supernatant from a C. neoformans broth culture (24). The predominant products in CneF are polysaccharide capsule (glucuronoxylomannan and galactoxylomannan) and a Con A-binding mannoprotein (24). Two blocks of gelatin sponges (17 x 18 x 10 mm, Gelfoam sterile absorbable gelatin sponge; The Upjohn Co., Kalamazoo, MI) were implanted s.c. Four days after implantation, one sponge was injected with 0.1 ml CneF and the other with 0.1 ml saline. The sponges were removed 24 h after sponge injection. Sponges were digested and dispersed with an enzyme mixture followed by lysis of erythrocytes. Viable cell counts were made using a hemocytometer and trypan blue exclusion. Cell differentials were determined with a modified Wright-Giemsa stain. The results represent specific leukocyte recruitment in response to CneF challenge and are expressed as the difference in total leukocytes between the CneF sponges and the saline only sponges.


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
The studies were performed with CCR5 knockout mice (CCR5-/-) generated by targeted deletion of the entire CCR5 coding exon without disruption of the CCR2 gene (4). As reported previously for this type of knockout, CCR5-/- mice develop normally; do not have observable histological abnormalities in the lungs, brain, spleen, or other organs compared with wild-type mice (CCR5+/+); and have no overt defects in T cell or macrophage numbers in the spleen or lungs (13). CCR5 knockout mice also do not display major defects in leukocyte recruitment as reported for CCR1 and CCR2 knockout mice (13, 14, 15, 16, 17, 18, 25, 26). CCR5-/- mice do not differ from CCR5+/+ mice in numbers of elicited macrophages after i.p. thioglycolate (13) or in size of liver granuloma formation after i.v. zymosan or glucan (W. A. Kuziel et al., manuscript in preparation). CCR5-/- mice also do not differ significantly from CCR5+/+ mice in survival after intratracheal inoculation of Klebsiella pneumoniae (data not shown). CCR5-/- mice display slightly reduced clearance of Listeria from the liver but not the spleen and have moderately reduced survival after intermediate but not high or low dose LPS treatment (13). Thus, the relatively normal immunological phenotype of the CCR5-/- mouse appears to be consistent with the normal immune status reported for humans possessing mutant copies of the CCR5 gene (9, 10, 11, 12).

To test whether expression of CCR5 is required for protection against C. neoformans, CCR5+/+ and CCR5-/- mice were inoculated intratracheally with 104 CFU of C. neoformans (strain 145). Intratracheal inoculation of this highly virulent strain of C. neoformans causes a pulmonary infection in immunocompetent mice that disseminates from the lungs by wk 2 and establishes an infection in the CNS (23). Greater than 90% of the CCR5+/+ mice infected with C. neoformans survived through wk 12 (Fig. 1Go). In contrast, less than 25% of the CCR5-/- mice survived (median, 8.4 wk) through wk 12 (Fig. 1Go). These experiments demonstrated that expression of CCR5 is required for host defense and survival after pulmonary-acquired C. neoformans infection.



View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 1. Survival of CCR5+/+ and CCR5-/- mice after C. neoformans infection. CCR5+/+ and CCR5-/- mice were inoculated intratracheally with 104 CFU of C. neoformans strain 145. (CCR5+/+) n = 18; (CCR5-/-) n = 31. p < 0.01

 
We next investigated whether the striking decrease in survival of CCR5-deficient mice was due to an inability to recruit leukocytes into the lungs and control the pulmonary infection. CCR5 expression in the lungs during a C. neoformans infection was readily detected in CCR5+/+ but not CCR5-/- mice (data not shown). To quantitate the leukocytic infiltrate in the lungs in response to C. neoformans infection, total lung leukocytes were isolated by enzymatic dispersion of the lungs and then counted (23). Deletion of CCR5 did not inhibit leukocyte recruitment into the lungs; rather, there was a trend toward increased leukocyte recruitment in CCR5-/- mice (7.42 ± 2.66 x 107 (+/+) vs 8.78 ± 3.78 x 107 (-/-) lung leukocytes at wk 5, p > 0.05). This was predominantly due to increased mononuclear cell recruitment in CCR5-/- mice (51% (+/+) vs 64% (-/-)). The leukocytic infiltrate in the lungs of C. neoformans-infected CCR5+/+ and CCR5-/- mice is clearly evident in histological sections (Fig. 2Go). Interestingly, CCR5-/- mice had lower lung CFU of C. neoformans at this time point than CCR5+/+ mice (7.54 ± 0.29 (+/+) vs 6.04 ± 0.31 (-/-) log10 CFU; p < 0.05). These results demonstrated that CCR5 is expressed in the lungs during a C. neoformans infection but that expression of CCR5 is not absolutely required for leukocyte recruitment into the lungs or to control the pulmonary C. neoformans infection.



View larger version (97K):
[in this window]
[in a new window]
  		FIGURE 2. Photomicrograph of the lungs from uninfected mice (A), C. neoformans-infected CCR5+/+ mice at wk 5 (B), or C. neoformans-infected CCR5-/- mice at wk 5 (C). Both CCR5+/+ and CCR5-/- mice have a prominent leukocytic infiltrate. Hematoxylin and eosin, x132.

 
We then analyzed the role of CCR5 in protecting against dissemination and growth of C. neoformans in the brain. At wk 2, the infection had not disseminated from the lungs to the brain in either group of mice (<100 CFU, data not shown). At wk 5, low level dissemination to the brain was evident in both CCR5+/+ and CCR5-/- mice (3.03 ± 0.82 (+/+) vs 2.52 ± 0.85 (-/-) log10 CFU). After wk 5, C. neoformans-infected CCR5-/- mice displayed clinical manifestations before death that were consistent with cryptococcal "meningitis" (cranial swelling, ruffled fur, staggered gait, lethargy and unresponsiveness, and decreased limb function). In contrast, C. neoformans-infected CCR5+/+ mice did not develop these symptoms. By wk 8, both groups of mice had equivalent colonization of the brain (7.52 ± 0.30 (+/+) vs 7.53 ± 0.55 (-/-) log10 CFU of wk 8 survivors), but 40% of the CCR5-/- mice had already died by wk 8 (Fig. 1Go), displaying signs of severe CNS infection before death. Further histological analysis revealed minimal mononuclear leukocyte recruitment into the brains of CCR5-deficient mice (Fig. 3Go). In sharp contrast, significant numbers of mononuclear leukocytes were recruited into the meninges of CCR5+/+ mice after colonization by C. neoformans (Fig. 3Go). This was consistent with previous studies demonstrating that growth of C. neoformans in the brain of immunocompetent mice stimulates the recruitment of leukocytes into the CNS (reviewed in Refs.21, 22). Thus, our studies demonstrate that expression of CCR5 is required for leukocyte recruitment into the CNS during C. neoformans infection.



View larger version (84K):
[in this window]
[in a new window]
  		FIGURE 3. Photomicrograph of the brain from uninfected mice (A), C. neoformans-infected CCR5+/+ mice at wk 8 (B), or C. neoformans-infected CCR5-/- mice at week 8 (C). CCR5-/- mice have minimal leukocytic infiltrate but significant swelling and accumulation of cryptococcal capsule in the brain compared with CCR5+/+ mice. Some cryptococci are labeled in the photomicrograph (cn), and the swollen parenchymal tissue in CCR5-/- mice is indicated (sw). The labels on the photomicrographs illustrate the distension of the meninges (m) in CCR5-/- vs CCR5+/+ mice (pt, parenchymal tissue). Hematoxylin and eosin, x132.

 
The most striking histological feature was the excessive capsule deposition and swelling in the brains of CCR5-/- mice (Fig. 3GoC). Distension of the cranium and loss of neural tissue integrity was also clearly evident in gross necropsy of these mice, and altogether, the immunopathogenesis of the infection in the CNS correlated with the dramatic decrease in survival of CCR5-deficient mice. Large amounts of extracellular cryptococcal polysaccharide capsule accumulated in the brains of CCR5-/- mice as detected by mucicarmine stain (histology not shown). Cryptococci could be seen in sections from CCR5-/- mice as clusters of organisms (Fig. 3GoC), whereas only single yeast or small groups of organisms with minimal polysaccharide capsule were present in the brains of CCR5+/+ mice (Fig. 3GoB). One caveat is that the large amount of capsule in the brains of CCR5-/- mice could have interfered with the enumeration of brain CFU, leading to an underestimate of the cryptococcal burden in the brains of CCR5-/- mice. The clinical presentation and histological evidence in CCR5-/- mice are consistent with the cause of death being hydrocephalus due to excessive cryptococcal polysaccharide accumulation (and breakdown of the osmotic gradient in the brain). C. neoformans infections of the CNS are often referred to as "meningitis." However, the CNS pathology of a C. neoformans infection in CCR5-/- mice was strikingly similar to that in AIDS patients (27), and cranial swelling in C. neoformans-infected CCR5-/- mice was not due to inflammation of the meninges. Thus, CCR5 expression is critical for elimination of extracellular polysaccharide from the brain during C. neoformans infection.

CCR5 expression on T cells appears to correlate with a Th1 phenotype (8, 28, 29, 30); thus, we examined the role of CCR5 in the Th1-type response, DTH, to CneF (31). Two well-characterized in vivo DTH assays were used, footpad swelling and leukocyte influx into Ag-loaded gelatin sponges (31, 32). Influx of immune leukocytes into CneF sponges is an Ag-specific response (DTH) directed against a C. neoformans mannoprotein in CneF (33), and the CCR5 ligand MIP-1{alpha} is required for leukocyte recruitment (34). Mice were immunized by a single s.c. injection of CneF mixed in CFA and challenged with CneF (in the footpad or sponge) 1 wk later, as described previously (31, 32, 33, 34). Immune CCR5+/+ and CCR5-/- mice both developed comparable, vigorous footpad DTH responses to cryptococcal filtrate (CneF) Ag (~15 in-3, p > 0.05). Immune CCR5+/+ and CCR5-/- mice also had equivalent numbers of leukocytes infiltrating the CneF sponges (~33 x 106 leukocytes, p > 0.05). Leukocyte differentials in the Ag sponges of immune CCR5+/+ and CCR5-/- mice were identical: macrophages, 69–75%; neutrophils, 13–16%; eosinophils, 7–10%; and lymphocytes, 5–6%. Thus, CCR5 expression is not required for the development or manifestation of the Th1 cell-mediated DTH response to C. neoformans.

However, the sponge model experiments demonstrated a potentially novel role for CCR5 in leukocyte recruitment and recognition of C. neoformans by innate immunity. As previously described for other mouse strains (35), CneF instillation causes the influx of macrophages into the sponges of nonimmune CCR5+/+ mice (Fig. 4Go). Unexpectedly, few macrophages migrated into the CneF sponges in nonimmune CCR5-/- mice (an 80% decrease compared with CCR5+/+ mice (Fig. 4Go)). There is no overall defect in macrophage recruitment in CCR5-/- mice because macrophage recruitment is normal after thioglycolate instillation (13), DTH elicitation (described above), and pulmonary C. neoformans infection (Fig. 2Go). CneF is a concentrate of the products shed during growth of C. neoformans and is chemotactic for leukocytes (33, 35). The receptor for CneF-mediated chemotaxis is unknown; however, our studies demonstrate that CCR5 is required (directly or indirectly) for recruitment of macrophages in nonimmune mice in response to shed cryptococcal products.



View larger version (36K):
[in this window]
[in a new window]
  		FIGURE 4. Role of CCR5 in macrophage migration into CneF-instilled gelatin sponges in nonimmune mice. Sponges were implanted into CCR5+/+ and CCR5-/- mice, and CneF was injected into the sponges as described in Materials and Methods. The results represent specific macrophage recruitment in response to CneF challenge and are expressed as the difference in total macrophages between the CneF sponges and the saline only sponges. The CneF sponges from both CCR5+/+ and CCR5-/- nonimmune mice also contained 1 x 105 eosinophils and negligible numbers of lymphocytes and neutrophils (mean ± SEM of five mice per group). *, p < 0.05.

 
These studies have demonstrated that 1) a cell-mediated immune response to a single pathogen can be differentially regulated at different sites in the body (lungs vs brain), 2) CCR5 plays a role in tissue-specific recruitment of leukocytes, and 3) CCR5 is not required for leukocyte recruitment during a Th1 response but may play a role in innate recognition of shed microbial products. CCR5 deficiency prevents mononuclear cell recruitment only into the brain, not into the lungs (Figs. 2Go and 3Go). In contrast, T cell deficiency inhibits leukocyte recruitment into both the lungs and brain during a C. neoformans infection (reviewed in Refs. 19, 21). It is not clear at this point how CCR5 mediates tissue-specific trafficking during a cell-mediated immune response because CCR5 is also expressed on a number of parenchymal cells (5). However, these studies clearly demonstrate that CCR5 plays a critical role in trafficking of leukocytes to different tissue sites during infection.

One interesting feature of cryptococcal infections is that HIV-induced immunosuppression is by far the greatest predisposing factor for cryptococcal meningitis when compared with any other mechanism of immunosuppression (20). C. neoformans infections in the CNS occur late in the pathogenesis of HIV disease when the viral infection is well established (20). Our studies open the possibility that dysregulated macrophage CCR5 function (potentially caused by HIV or gp120 binding to CCR5) could be a significant predisposing factor for C. neoformans infection of the CNS. Also, in Africa and Asia where the rate of environmental C. neoformans exposure is high, CCR5 mutations are not found in the indigenous population (10, 12, 20). The studies presented here demonstrate that CCR5 plays a critical organ-specific role in host defense against disseminated C. neoformans infection and provide a testable hypothesis for why cryptococcal meningitis is far more prevalent in HIV-induced immunosuppression than any other type of immunosuppression.


   Footnotes
 
1 These studies have been supported in part by National Institutes of Health Grants R29-AI38190 (G.B.H.), R01-AI15716 (J.W.M.), R01-HL59852 (J.W.M.), R01-HL51082 (G.B.T.), and R01-HL42630 (N.M.); New Investigator Award in Molecular Pathogenic Mycology from the Burroughs-Wellcome Fund (G.B.H.); and an Institute for Cellular and Molecular Biology Research Grant (W.A.K.). Back

2 Address correspondence and reprint requests to Dr. B. Huffnagle, Pulmonary and Critical Care Medicine Division, Department of Internal Medicine, 6301 MSRB III, Box 0642, University of Michigan Medical Center, Ann Arbor, MI 48109-0642. E-mail address: Back

3 Abbreviations used in this paper: MIP-1, macrophage inflammatory protein-1; CneF, Cryptococcus neoformans filtrate Ag; DTH, delayed-type hypersensitivity. Back

4 W. A. Kuziel, T. C. Dawson, R. L. Reddick, and N. Maeda. Atherogenesis in apolipoprotein E-deficient mice that also lack the chemokine receptor CCR5. Submitted for publication. Back

Received for publication June 25, 1999. Accepted for publication September 2, 1999.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, E. A. Berger. 1996. CC CKR5: a RANTES, MIP-1{alpha}, MIP-1ß receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272:1955.[Abstract]
  2. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, J. Sodroski. 1996. The ß-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135.[Medline]
  3. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661.[Medline]
  4. Dragic, T., V. Litwin, G. P. Allaway, S. R. Martin, Y. Huang, K. A. Nagashima, C. Cayanan, P. J. Maddon, R. A. Koup, J. P. Moore, W. A. Paxton. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667.[Medline]
  5. Rottman, J. B., K. P. Ganley, K. Williams, L. Wu, C. R. Mackay, D. J. Ringler. 1997. Cellular localization of the chemokine receptor CCR5: correlation to cellular targets of HIV-1 infection. Am. J. Pathol. 151:1341.[Abstract]
  6. Raport, C. J., J. Gosling, V. L. Schweickart, P. W. Gray, I. F. Charo. 1996. Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1ß, and MIP-1{alpha}. J. Biol. Chem. 271:17161.[Abstract/Free Full Text]
  7. Samson, M., O. Labbe, C. Mollereau, G. Vassart, M. Parmentier. 1996. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 35:3362.[Medline]
  8. Qin, S., J. B. Rottman, P. Myers, N. Kassam, M. Weinblatt, M. Loetscher, A. E. Koch, B. Moser, C. R. Mackay. 1998. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. 101:746.[Medline]
  9. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, et al 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. [Published erratum appears in Science 1996 Nov 15;274(5290):1069]. Science 273:1856.[Abstract/Free Full Text]
  10. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, et al 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240.[Medline]
  11. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367.[Medline]
  12. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722.
  13. Zhou, Y., T. Kurihara, R. P. Ryseck, Y. Yang, C. Ryan, J. Loy, G. Warr, R. Bravo. 1998. Impaired macrophage function and enhanced T cell-dependent immune response in mice lacking CCR5, the mouse homologue of the major HIV-1 coreceptor. J. Immunol. 160:4018.[Abstract/Free Full Text]
  14. Kurihara, T., G. Warr, J. Loy, R. Bravo. 1997. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med. 186:1757.[Abstract/Free Full Text]
  15. Boring, L., J. Gosling, S. W. Chensue, S. L. Kunkel, Jr R. V. Farese, H. E. Broxmeyer, I. F. Charo. 1997. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100:2552.[Medline]
  16. Gerard, C., J. L. Frossard, M. Bhatia, A. Saluja, N. P. Gerard, B. Lu, M. Steer. 1997. Targeted disruption of the ß-chemokine receptor CCR1 protects against pancreatitis-associated lung injury. J. Clin. Invest. 100:2022.[Medline]
  17. Kuziel, W. A., S. J. Morgan, T. C. Dawson, S. Griffin, O. Smithies, K. Ley, N. Maeda. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. USA 94:12053.[Abstract/Free Full Text]
  18. Gao, J. L., T. A. Wynn, Y. Chang, E. J. Lee, H. E. Broxmeyer, S. Cooper, H. L. Tiffany, H. Westphal, J. Kwon-Chung, P. M. Murphy. 1997. Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1. J. Exp. Med. 185:1959.[Abstract/Free Full Text]
  19. Huffnagle, G. B., M. F. Lipscomb. 1998. Cells and cytokines in pulmonary cryptococcosis. Res. Immunol. 149:387.[Medline]
  20. Casadevall, A., J. R. Perfect. 1998. Cryptococcus neoformans ASM Press, Washington, DC.
  21. Huffnagle, G. B., L. K. McNeil. 1999. Dissemination of C. neoformans to the central nervous system: role of Th1 immunity, leukocyte recruitment, and chemokines. J. Neurovirol. 5:76.[Medline]
  22. Goldman, D. L., A. Casadevall, Y. Cho, S. C. Lee. 1996. Cryptococcus neoformans meningitis in the rat. Lab. Invest. 75:759.[Medline]
  23. Huffnagle, G. B., G. H. Chen, J. L. Curtis, R. A. McDonald, R. M. Strieter, G. B. Toews. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155:3507.[Abstract]
  24. Murphy, J. W., R. L. Mosley, R. Cherniak, G. H. Reyes, T. R. Kozel, E. Reiss. 1988. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect. Immun. 56:424.[Abstract/Free Full Text]
  25. Boring, L., J. Gosling, M. Cleary, I. F. Charo. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894.[Medline]
  26. Dawson, T. C., W. A. Kuziel, T. A. Osahar, N. Maeda. 1999. Absence of CC chemokine receptor 2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143:205.[Medline]
  27. Lee, S. C., D. W. Dickson, A. Casadevall. 1996. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications. Hum. Pathol. 27:839.[Medline]
  28. Sallusto, F., D. Lenig, C. R. Mackay, A. Lanzavecchia. 1998. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187:875.[Abstract/Free Full Text]
  29. Bonecchi, R., G. Bianchi, P. P. Bordignon, D. A. D. R. Lang, A. Borsatti, S. Sozzani, P. Allavena, P. A. Gray, A. Mantovani, F. Sinigaglia. 1998. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187:129.[Abstract/Free Full Text]
  30. Loetscher, P., M. Uguccioni, L. Bordoli, M. Baggiolini, B. Moser, C. Chizzolini, J. M. Dayer. 1998. CCR5 is characteristic of Th1 lymphocytes. Nature 391:344.[Medline]
  31. Buchanan, K. L., J. W. Murphy. 1993. Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response. Infect. Immun. 61:2854.[Abstract/Free Full Text]
  32. Murphy, J. W., N. Pahlavan. 1979. Cryptococcal culture filtrate antigen for detection of delayed-type hypersensitivity in cryptococcosis. Infect. Immun. 25:284.[Abstract/Free Full Text]
  33. Dong, Z. M., J. W. Murphy. 1993. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen. Infect. Immun. 61:5067.[Abstract/Free Full Text]
  34. Doyle, H. A., J. W. Murphy. 1997. MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J. Leukocyte Biol. 61:147.[Abstract]
  35. Dong, Z. M., J. W. Murphy. 1995. Intravascular cryptococcal culture filtrate (CneF) and its major component, glucuronoxylomannan, are potent inhibitors of leukocyte accumulation. Infect. Immun. 63:770.[Abstract]



This article has been cited by other articles:


Home page
 BloodHome page
D. Zhao, C. Zhang, T. Yi, C.-L. Lin, I. Todorov, F. Kandeel, S. Forman, and D. Zeng
In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease
Blood, September 1, 2008; 112(5): 2129 - 2138.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. J. Osterholzer, J. L. Curtis, T. Polak, T. Ames, G.-H. Chen, R. McDonald, G. B. Huffnagle, and G. B. Toews
CCR2 Mediates Conventional Dendritic Cell Recruitment and the Formation of Bronchovascular Mononuclear Cell Infiltrates in the Lungs of Mice Infected with Cryptococcus neoformans
J. Immunol., July 1, 2008; 181(1): 610 - 620.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Kallikourdis, K. G. Andersen, K. A. Welch, and A. G. Betz
Alloantigen-enhanced accumulation of CCR5+ 'effector' regulatory T cells in the gravid uterus
PNAS, January 9, 2007; 104(2): 594 - 599.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Venkataramana, C. A. Pardo, J. C. McArthur, D. A. Kerr, D. N. Irani, J. W. Griffin, P. Burger, D. S. Reich, P. A. Calabresi, and A. Nath
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients
Neurology, August 8, 2006; 67(3): 383 - 388.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Zernecke, E. A. Liehn, J.-L. Gao, W. A. Kuziel, P. M. Murphy, and C. Weber
Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10
Blood, June 1, 2006; 107(11): 4240 - 4243.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. Ma, W. Liu, R. J. Homer, P. J. Lee, A. J. Coyle, J. M. Lora, C. G. Lee, and J. A. Elias
Role of CCR5 in the Pathogenesis of IL-13-Induced Inflammation and Remodeling.
J. Immunol., April 15, 2006; 176(8): 4968 - 4978.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
D. J. J. Carr, J. Ash, T. E. Lane, and W. A. Kuziel
Abnormal immune response of CCR5-deficient mice to ocular infection with herpes simplex virus type 1.
J. Gen. Virol., March 1, 2006; 87(Pt 3): 489 - 499.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. L. Hardison, R. A. Wrightsman, P. M. Carpenter, W. A. Kuziel, T. E. Lane, and J. E. Manning
The CC Chemokine Receptor 5 Is Important in Control of Parasite Replication and Acute Cardiac Inflammation following Infection with Trypanosoma cruzi
Infect. Immun., January 1, 2006; 74(1): 135 - 143.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. A. Wysocki, Q. Jiang, A. Panoskaltsis-Mortari, P. A. Taylor, K. P. McKinnon, L. Su, B. R. Blazar, and J. S. Serody
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease
Blood, November 1, 2005; 106(9): 3300 - 3307.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
W. G. Glass, J. K. Lim, R. Cholera, A. G. Pletnev, J.-L. Gao, and P. M. Murphy
Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection
J. Exp. Med., October 17, 2005; 202(8): 1087 - 1098.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Takashima, H. Miyake, N. Kanzaki, Y. Tagawa, X. Wang, Y. Sugihara, Y. Iizawa, and M. Baba
Highly Potent Inhibition of Human Immunodeficiency Virus Type 1 Replication by TAK-220, an Orally Bioavailable Small-Molecule CCR5 Antagonist
Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3474 - 3482.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Ank, K. Petersen, L. Malmgaard, S. C. Mogensen, and S. R. Paludan
Age-Dependent Role for CCR5 in Antiviral Host Defense against Herpes Simplex Virus Type 2
J. Virol., August 1, 2005; 79(15): 9831 - 9841.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
H. M. Scott Algood and J. L. Flynn
CCR5-Deficient Mice Control Mycobacterium tuberculosis Infection despite Increased Pulmonary Lymphocytic Infiltration
J. Immunol., September 1, 2004; 173(5): 3287 - 3296.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. E. Peterson, J. S. Errett, T. Wei, D. E. Dimcheff, R. Ransohoff, W. A. Kuziel, L. Evans, and B. Chesebro
MCP-1 and CCR2 Contribute to Non-Lymphocyte-Mediated Brain Disease Induced by Fr98 Polytropic Retrovirus Infection in Mice: Role for Astrocytes in Retroviral Neuropathogenesis
J. Virol., June 15, 2004; 78(12): 6449 - 6458.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
M. X. Zhong, W. A. Kuziel, E. G. Pamer, and N. V. Serbina
Chemokine Receptor 5 Is Dispensable for Innate and Adaptive Immune Responses to Listeria monocytogenes Infection
Infect. Immun., February 1, 2004; 72(2): 1057 - 1064.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
V. Eis, B. Luckow, V. Vielhauer, J. T. Siveke, Y. Linde, S. Segerer, G. P. de Lema, C. D. Cohen, M. Kretzler, M. Mack, et al.
Chemokine Receptor CCR1 But Not CCR5 Mediates Leukocyte Recruitment and Subsequent Renal Fibrosis after Unilateral Ureteral Obstruction
J. Am. Soc. Nephrol., February 1, 2004; 15(2): 337 - 347.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
I. Szabo, M. A. Wetzel, N. Zhang, A. D. Steele, D. E. Kaminsky, C. Chen, L.-Y. Liu-Chen, F. Bednar, E. E. Henderson, O. M. Z. Howard, et al.
Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization
J. Leukoc. Biol., December 1, 2003; 74(6): 1074 - 1082.
[Abstract] [Full Text]

Home page
 BloodHome page
E. Belnoue, M. Kayibanda, J.-C. Deschemin, M. Viguier, M. Mack, W. A. Kuziel, and L. Renia
CCR5 deficiency decreases susceptibility to experimental cerebral malaria
Blood, June 1, 2003; 101(11): 4253 - 4259.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. E. Cardona, P. A. Gonzalez, and J. M. Teale
CC Chemokines Mediate Leukocyte Trafficking into the Central Nervous System during Murine Neurocysticercosis: Role of {gamma}{delta} T Cells in Amplification of the Host Immune Response
Infect. Immun., May 1, 2003; 71(5): 2634 - 2642.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
B. K. Ambati, A. Anand, A. M. Joussen, W. A. Kuziel, A. P. Adamis, and J. Ambati
Sustained Inhibition of Corneal Neovascularization by Genetic Ablation of CCR5
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 590 - 593.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
W. G. Glass and T. E. Lane
Functional Expression of Chemokine Receptor CCR5 on CD4+ T Cells during Virus-Induced Central Nervous System Disease
J. Virol., December 6, 2002; 77(1): 191 - 198.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Nansen, J. P. Christensen, S. O. Andreasen, C. Bartholdy, J. E. Christensen, and A. R. Thomsen
The role of CC chemokine receptor 5 in antiviral immunity
Blood, February 15, 2002; 99(4): 1237 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. B. Moore, R. Paine III, P. J. Christensen, T. A. Moore, S. Sitterding, R. Ngan, C. A. Wilke, W. A. Kuziel, and G. B. Toews
Protection from Pulmonary Fibrosis in the Absence of CCR2 Signaling
J. Immunol., October 15, 2001; 167(8): 4368 - 4377.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
B. P. Chen, W. A. Kuziel, and T. E. Lane
Lack of CCR2 Results in Increased Mortality and Impaired Leukocyte Activation and Trafficking Following Infection of the Central Nervous System with a Neurotropic Coronavirus
J. Immunol., October 15, 2001; 167(8): 4585 - 4592.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
M. A. Olszewski, G. B. Huffnagle, T. R. Traynor, R. A. McDonald, D. N. Cook, and G. B. Toews
Regulatory Effects of Macrophage Inflammatory Protein 1{alpha}/CCL3 on the Development of Immunity to Cryptococcus neoformans Depend on Expression of Early Inflammatory Cytokines
Infect. Immun., October 1, 2001; 69(10): 6256 - 6263.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Mack, J. Cihak, C. Simonis, B. Luckow, A. E. I. Proudfoot, H. Bruhl, M. Frink, H.-J. Anders, V. Vielhauer, J. Pfirstinger, et al.
Expression and Characterization of the Chemokine Receptors CCR2 and CCR5 in Mice
J. Immunol., April 1, 2001; 166(7): 4697 - 4704.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
D. Goldman, X. Song, R. Kitai, A. Casadevall, M.-L. Zhao, and S. C. Lee
Cryptococcus neoformans Induces Macrophage Inflammatory Protein 1{alpha} (MIP-1{alpha}) and MIP-1{beta} in Human Microglia: Role of Specific Antibody and Soluble Capsular Polysaccharide
Infect. Immun., March 1, 2001; 69(3): 1808 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Unutmaz, W. Xiang, M. J. Sunshine, J. Campbell, E. Butcher, and D. R. Littman
The Primate Lentiviral Receptor Bonzo/STRL33 Is Coordinately Regulated with CCR5 and Its Expression Pattern Is Conserved Between Human and Mouse
J. Immunol., September 15, 2000; 165(6): 3284 - 3292.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Blease, B. Mehrad, T. J. Standiford, N. W. Lukacs, J. Gosling, L. Boring, I. F. Charo, S. L. Kunkel, and C. M. Hogaboam
Enhanced Pulmonary Allergic Responses to Aspergillus in CCR2-/- Mice
J. Immunol., September 1, 2000; 165(5): 2603 - 2611.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. C. Dawson, M. A. Beck, W. A. Kuziel, F. Henderson, and N. Maeda
Contrasting Effects of CCR5 and CCR2 Deficiency in the Pulmonary Inflammatory Response to Influenza A Virus
Am. J. Pathol., June 1, 2000; 156(6): 1951 - 1959.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
P. M. Murphy, M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim, and C. A. Power
International Union of Pharmacology. XXII. Nomenclature for Chemokine Receptors
Pharmacol. Rev., March 1, 2000; 52(1): 145 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Sato, W. A. Kuziel, P. C. Melby, R. L. Reddick, V. Kostecki, W. Zhao, N. Maeda, S. K. Ahuja, and S. S. Ahuja
Defects in the Generation of IFN-{gamma} Are Overcome to Control Infection with Leishmania donovani in CC Chemokine Receptor (CCR) 5-, Macrophage Inflammatory Protein-1{alpha}-, or CCR2-Deficient Mice
J. Immunol., November 15, 1999; 163(10): 5519 - 5525.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Dragic, A. Trkola, D. A. D. Thompson, E. G. Cormier, F. A. Kajumo, E. Maxwell, S. W. Lin, W. Ying, S. O. Smith, T. P. Sakmar, et al.
A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5
PNAS, May 9, 2000; 97(10): 5639 - 5644.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. Strizki, S. Xu, N. E. Wagner, L. Wojcik, J. Liu, Y. Hou, M. Endres, A. Palani, S. Shapiro, J. W. Clader, et al.
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
PNAS, October 23, 2001; 98(22): 12718 - 12723.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huffnagle, G. B.
Right arrow Articles by Kuziel, W. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huffnagle, G. B.
Right arrow Articles by Kuziel, W. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS